[Laxatives: marketing, mechanism of action and clinical effects].

E. Materia,G. Bausano,E. Corazziari

1984-02-01

Abstract:

What problem does this paper attempt to address?

Development of Extracellular Vesicle Therapeutics: Challenges, Considerations, and Opportunities

Bethany Claridge,Jonathan Lozano,Qi Hui Poh,David W. Greening

DOI: https://doi.org/10.3389/fcell.2021.734720

IF: 5.5

2021-09-20

Frontiers in Cell and Developmental Biology

Abstract:Extracellular vesicles (EVs) hold great promise as therapeutic modalities due to their endogenous characteristics, however, further bioengineering refinement is required to address clinical and commercial limitations. Clinical applications of EV-based therapeutics are being trialed in immunomodulation, tissue regeneration and recovery, and as delivery vectors for combination therapies. Native/biological EVs possess diverse endogenous properties that offer stability and facilitate crossing of biological barriers for delivery of molecular cargo to cells, acting as a form of intercellular communication to regulate function and phenotype. Moreover, EVs are important components of paracrine signaling in stem/progenitor cell-based therapies, are employed as standalone therapies, and can be used as a drug delivery system. Despite remarkable utility of native/biological EVs, they can be improved using bio/engineering approaches to further therapeutic potential. EVs can be engineered to harbor specific pharmaceutical content, enhance their stability, and modify surface epitopes for improved tropism and targeting to cells and tissues in vivo . Limitations currently challenging the full realization of their therapeutic utility include scalability and standardization of generation, molecular characterization for design and regulation, therapeutic potency assessment, and targeted delivery. The fields’ utilization of advanced technologies (imaging, quantitative analyses, multi-omics, labeling/live-cell reporters), and utility of biocompatible natural sources for producing EVs (plants, bacteria, milk) will play an important role in overcoming these limitations. Advancements in EV engineering methodologies and design will facilitate the development of EV-based therapeutics, revolutionizing the current pharmaceutical landscape.

cell biology,developmental biology
Engineering Extracellular Vesicles as Delivery Systems in Therapeutic Applications

Liwei Wang,Di Wang,Zhaoming Ye,Jianbin Xu

DOI: https://doi.org/10.1002/advs.202300552

IF: 15.1

2023-04-22

Advanced Science

Abstract:Extracellular vesicles (EVs) are reshaping the perspective on life science and public health. Although many EV‐based therapies have been shown to delay disease progression, the issue of EV purity and yield is a huge hurdle to overcome. In the future, how to balance the drug delivery efficiency, targeting ability, molecular activity and economic cost of EV therapeutics are also major issues worthy of research exploration. Extracellular vesicles (EVs) are transport vesicles secreted by living cells and released into the extracellular environment. Recent studies have shown that EVs serve as "messengers" in intercellular and inter‐organismal communication, in both normal and pathological processes. EVs, as natural nanocarriers, can deliver bioactivators in therapy with their endogenous transport properties. This review article describes the engineering EVs of sources, isolation method, cargo loading, boosting approach, and adjustable targeting of EVs. Furthermore, the review summarizes the recent progress made in EV‐based delivery systems applications, including cancer, cardiovascular diseases, liver, kidney, nervous system diseases, and COVID‐19 and emphasizes the obstacles and challenges of EV‐based therapies and possible strategies.

materials science, multidisciplinary,nanoscience & nanotechnology,chemistry
Extracellular Vesicles As Nanomedicine: Hopes And Hurdles In Clinical Translation

Thierry Burnouf,Vibhuti Agrahari,Vivek Agrahari

DOI: https://doi.org/10.2147/IJN.S225453

2019-11-12

Abstract:The clinical development of cell therapies is revealing that extracellular vesicles (EVs) may become very instrumental as subcellular therapeutic adjuncts in human medicine. EVs are released by various types of cells, grown in culture, such as mesenchymal stromal cells, or obtained from patients or allogeneic donors. Some EV populations (especially species of exosomes and shed microvesicles) exhibit inherent roles in cell-cell communication, thanks to their ca. 30~1000-nm nanosize and the physiological expression of cell-specific markers on their lipid bilayer membranes. Biomedical engineers are now attempting to exploit this cellular crosstalk capacity to use EVs as smart drug delivery systems that display substantial benefits in targeting, safety, and pharmacokinetics compared to synthetic nanocarriers. In parallel, the development of a set of nano-instrumentation, biochemical tools, and preclinical assays needed for optimal characterization of both naïve and drug-loaded EVs is ongoing. Although many hurdles remain, owing to the complexity of EV populations, translation of this "subcellular therapy" platform into reality is at hand and may soon change the landscape of the therapeutic arsenal in place to treat human degenerative and metabolic pathologies as well as diseases like cancer. This article provides objective opinions, balanced between unrealistic hopes of the capacity of EVs to resolve multiple clinical issues and concrete hurdles that have to be overcome to ensure that EVs are not lost in the translation phase, so that EVs can fulfill their promise by becoming a reliable therapeutic modality.
Biological Functions and Biomedical Applications of Extracellular Vesicles Derived from Blood Cells

Kaifeng Pan,Yiwei Zhu,Pengyu Chen,Ke Yang,Yiyu Chen,Yongcheng Wang,Zhanqiu Dai,Zhenxiang Huang,Peiyu Zhong,Xing Zhao,Shunwu Fan,Lei Ning,Jianfeng Zhang,Pengfei Chen

DOI: https://doi.org/10.1016/j.freeradbiomed.2024.06.002

IF: 8.101

2024-01-01

Free Radical Biology and Medicine

Abstract:There is a growing interest in using extracellular vesicles (EVs) for therapeutic applications. EVs are composed of cytoplasmic proteins and nucleic acids and an external lipid bilayer containing transmembrane proteins on their surfaces. EVs can alter the state of the target cells by interacting with the receptor ligand of the target cell or by being internalised by the target cell. Blood cells are the primary source of EVs, and 1 μL of plasma contains approximately 1.5×107 EVs. Owing to their easy acquisition and the avoidance of cell amplification in vitro, using blood cells as a source of therapeutic EVs has promising clinical application prospects. This review summarises the characteristics and biological functions of EVs derived from different blood cell types (platelets, erythrocytes, and leukocytes) and analyses the prospects and challenges of using them for clinical therapeutic applications. In summary, blood cell-derived EVs can regulate different cell types such as immune cells (macrophages, T cells, and dendritic cells), stem cells, and somatic cells, and play a role in intercellular communication, immune regulation, and cell proliferation. Overall, blood cell-derived EVs have the potential for use in vascular diseases, inflammatory diseases, degenerative diseases, and injuries. To promote the clinical translation of blood cell-derived EVs, researchers need to perform further studies on EVs in terms of scalable and reproducible isolation technology, quality control, safety, stability and storage, regulatory issues, cost-effectiveness, and long-term efficacy.
Engineered Extracellular Vesicles: Tailored-Made Nanomaterials for Medical Applications

Kenny Man,Mathieu Y. Brunet,Marie-Christine Jones,Sophie C. Cox

DOI: https://doi.org/10.3390/nano10091838

IF: 5.3

2020-09-15

Nanomaterials

Abstract:Extracellular vesicles (EVs) are emerging as promising nanoscale therapeutics due to their intrinsic role as mediators of intercellular communication, regulating tissue development and homeostasis. The low immunogenicity and natural cell-targeting capabilities of EVs has led to extensive research investigating their potential as novel acellular tools for tissue regeneration or for the diagnosis of pathological conditions. However, the clinical use of EVs has been hindered by issues with yield and heterogeneity. From the modification of parental cells and naturally-derived vesicles to the development of artificial biomimetic nanoparticles or the functionalisation of biomaterials, a multitude of techniques have been employed to augment EVs therapeutic efficacy. This review will explore various engineering strategies that could promote EVs scalability and therapeutic effectiveness beyond their native utility. Herein, we highlight the current state-of-the-art EV-engineering techniques with discussion of opportunities and obstacles for each. This is synthesised into a guide for selecting a suitable strategy to maximise the potential efficacy of EVs as nanoscale therapeutics.

materials science, multidisciplinary,physics, applied,nanoscience & nanotechnology,chemistry
Extracellular vesicles: Emerging tools as therapeutic agent carriers

Shan Liu,Xue Wu,Sutapa Chandra,Christopher Lyon,Bo Ning,Li jiang,Jia Fan,Tony Y. Hu

DOI: https://doi.org/10.1016/j.apsb.2022.05.002

IF: 14.903

2022-10-01

Acta Pharmaceutica Sinica B

Abstract:Extracellular vesicles (EVs) are secreted by both eukaryotes and prokaryotes, and are present in all biological fluids of vertebrates, where they transfer DNA, RNA, proteins, lipids, and metabolites from donor to recipient cells in cell-to-cell communication. Some EV components can also indicate the type and biological status of their parent cells and serve as diagnostic targets for liquid biopsy. EVs can also natively carry or be modified to contain therapeutic agents (e.g., nucleic acids, proteins, polysaccharides, and small molecules) by physical, chemical, or bioengineering strategies. Due to their excellent biocompatibility and stability, EVs are ideal nanocarriers for bioactive ingredients to induce signal transduction, immunoregulation, or other therapeutic effects, which can be targeted to specific cell types. Herein, we review EV classification, intercellular communication, isolation, and characterization strategies as they apply to EV therapeutics. This review focuses on recent advances in EV applications as therapeutic carriers from in vitro research towards in vivo animal models and early clinical applications, using representative examples in the fields of cancer chemotherapeutic drug, cancer vaccine, infectious disease vaccines, regenerative medicine and gene therapy. Finally, we discuss current challenges for EV therapeutics and their future development.

pharmacology & pharmacy
Engineered Extracellular Vesicles: A Potential Treatment for Regeneration

Wen Cheng,Chenyu Xu,Yuran Su,Youqing Shen,Qiang Yang,Yanmei Zhao,Yanhong Zhao,Yue Liu

DOI: https://doi.org/10.1016/j.isci.2023.108282

IF: 5.8

2023-01-01

iScience

Abstract:Extracellular vesicles (EVs) play a critical role in various physiological and pathological processes. EVs have gained recognition in regenerative medicine due to their biocompatibility and low immunogenicity. However, the practical application of EVs faces challenges such as limited targeting ability, low yield, and inadequate therapeutic effects. To overcome these limitations, engineered EVs have emerged. This review aims to comprehensively analyze the engineering methods utilized for modifying donor cells and EVs, with a focus on comparing the therapeutic potential between engineered and natural EVs. Additionally, it aims to investigate the specific cell effects that play a crucial role in promoting repair and regeneration, while also exploring the underlying mechanisms involved in the field of regenerative medicine.
Advances of engineered extracellular vesicles-based therapeutics strategy

Hiroaki Komuro,Shakhlo Aminova,Katherine Lauro,Masako Harada

DOI: https://doi.org/10.1080/14686996.2022.2133342

IF: 7.821

2022-10-21

Science and Technology of Advanced Materials

Abstract:Extracellular vesicles (EVs) are a heterogeneous population of lipid bilayer membrane-bound vesicles which encapsulate bioactive molecules, such as nucleic acids, proteins, and lipids. They mediate intercellular communication through transporting internally packaged molecules, making them attractive therapeutics carriers. Over the last decades, a significant amount of research has implied the potential of EVs servings as drug delivery vehicles for nuclear acids, proteins, and small molecular drugs. However, several challenges remain unresolved before the clinical application of EV-based therapeutics, including lack of specificity, stability, biodistribution, storage, large-scale manufacturing, and the comprehensive analysis of EV composition. Technical development is essential to overcome these issues and enhance the pre-clinical therapeutic effects. In this review, we summarize the current advancements in EV engineering which demonstrate their therapeutic potential. GRAPHICAL

materials science, multidisciplinary
Therapeutic Applications of Extracellular Vesicles: Clinical Promise and Open Questions

Bence György,Michelle E. Hung,Xandra O. Breakefield,Joshua N. Leonard

DOI: https://doi.org/10.1146/annurev-pharmtox-010814-124630

2015-01-06

Abstract:This review provides an updated perspective on rapidly proliferating efforts to harness extracellular vesicles (EVs) for therapeutic applications. We summarize current knowledge, emerging strategies, and open questions pertaining to clinical potential and translation. Potentially useful EVs comprise diverse products of various cell types and species. EV components may also be combined with liposomes and nanoparticles to facilitate manufacturing as well as product safety and evaluation. Potential therapeutic cargoes include RNA, proteins, and drugs. Strategic issues considered herein include choice of therapeutic agent, means of loading cargoes into EVs, promotion of EV stability, tissue targeting, and functional delivery of cargo to recipient cells. Some applications may harness natural EV properties, such as immune modulation, regeneration promotion, and pathogen suppression. These properties can be enhanced or customized to enable a wide range of therapeutic applications, including vaccination, improvement of pregnancy outcome, and treatment of autoimmune disease, cancer, and tissue injury.

pharmacology & pharmacy,toxicology
Different Sourced Extracellular Vesicles and Their Potential Applications in Clinical Treatments

Leila Bahmani,Mujib Ullah

DOI: https://doi.org/10.3390/cells11131989

IF: 6

2022-06-22

Cells

Abstract:Extracellular vesicles (EVs) include a heterogeneous group of natural cell-derived nanostructures that are increasingly regarded as promising biotherapeutic agents and drug delivery vehicles in human medicine. Desirable intrinsic properties of EVs including the ability to bypass natural membranous barriers and to deliver their unique biomolecular cargo to specific cell populations position them as fiercely competitive alternatives for currently available cell therapies and artificial drug delivery platforms. EVs with distinct characteristics can be released from various cell types into the extracellular environment as a means of transmitting bioactive components and altering the status of the target cell. Despite the existence of a large number of preclinical studies confirming the therapeutic efficacy of different originated EVs for treating several pathological conditions, in this review, we first provide a brief overview of EV biophysical properties with an emphasis on their intrinsic therapeutic benefits over cell-based therapies and synthetic delivery systems. Next, we describe in detail different EVs derived from distinct cell sources, compare their advantages and disadvantages, and recapitulate their therapeutic effects on various human disorders to highlight the progress made in harnessing EVs for clinical applications. Finally, knowledge gaps and concrete hurdles that currently hinder the clinical translation of EV therapies are debated with a futuristic perspective.

cell biology
Extracellular Vesicles in Therapeutics: A Comprehensive Review on Applications, Challenges, and Clinical Progress

Jiyoung Goo,Yeji Lee,Jeongmin Lee,In-San Kim,Cherlhyun Jeong

DOI: https://doi.org/10.3390/pharmaceutics16030311

IF: 6.525

2024-02-23

Pharmaceutics

Abstract:Small Extracellular Vesicles (sEVs) are typically 30–150 nm in diameter, produced inside cells, and released into the extracellular space. These vesicles carry RNA, DNA, proteins, and lipids that reflect the characteristics of their parent cells, enabling communication between cells and the alteration of functions or differentiation of target cells. Owing to these properties, sEVs have recently gained attention as potential carriers for functional molecules and drug delivery tools. However, their use as a therapeutic platform faces limitations, such as challenges in mass production, purity issues, and the absence of established protocols and characterization methods. To overcome these, researchers are exploring the characterization and engineering of sEVs for various applications. This review discusses the origins of sEVs and their engineering for therapeutic effects, proposing areas needing intensive study. It covers the use of cell-derived sEVs in their natural state and in engineered forms for specific purposes. Additionally, the review details the sources of sEVs and their subsequent purification methods. It also outlines the potential of therapeutic sEVs and the requirements for successful clinical trials, including methods for large-scale production and purification. Finally, we discuss the progress of ongoing clinical trials and the implications for future healthcare, offering a comprehensive overview of the latest research in sEV applications.

pharmacology & pharmacy
Engineered Extracellular Vesicles as a Targeted Delivery Platform for Precision Therapy

Yuntong Sun,Fengtian Sun,Wenrong Xu,Hui Qian

DOI: https://doi.org/10.1007/s13770-022-00503-y

2023-01-14

Tissue Engineering and Regenerative Medicine

Abstract:Extracellular vesicles (EVs)-based cell-free strategy has shown therapeutic potential in tissue regeneration. Due to their important roles in intercellular communications and their natural ability to shield cargos from degradation, EVs are also emerged as novel delivery vehicles for various bioactive molecules and drugs. Accumulating studies have revealed that EVs can be modified to enhance their efficacy and specificity for the treatment of many diseases. Engineered EVs are poised as the next generation of targeted delivery platform in the field of precision therapy. In this review, the unique properties of EVs are overviewed in terms of their biogenesis, contents, surface features and biological functions, and the recent advances in the strategies of engineered EVs construction are summarized. Additionally, we also discuss the potential applications of engineered EVs in targeted therapy of cancer and damaged tissues, and evaluate the opportunities and challenges for translating them into clinical practice.

engineering, biomedical,cell & tissue engineering
From Promise to Reality: Bioengineering Strategies to Enhance the Therapeutic Potential of Extracellular Vesicles

Miguel de Almeida Fuzeta,Ana Fernandes-Platzgummer,Nuno Bernardes,Pedro P. Gonçalves,Joaquim M. S. Cabral,Cláudia L. da Silva

DOI: https://doi.org/10.3390/bioengineering9110675

IF: 5.046

2022-11-10

Bioengineering

Abstract:Extracellular vesicles (EVs) have been the focus of great attention over the last decade, considering their promising application as next-generation therapeutics. EVs have emerged as relevant mediators of intercellular communication, being associated with multiple physiological processes, but also in the pathogenesis of several diseases. Given their natural ability to shuttle messages between cells, EVs have been explored both as inherent therapeutics in regenerative medicine and as drug delivery vehicles targeting multiple diseases. However, bioengineering strategies are required to harness the full potential of EVs for therapeutic use. For that purpose, a good understanding of EV biology, from their biogenesis to the way they are able to shuttle messages and establish interactions with recipient cells, is needed. Here, we review the current state-of-the-art on EV biology, complemented by representative examples of EVs roles in several pathophysiological processes, as well as the intrinsic therapeutic properties of EVs and paradigmatic strategies to produce and develop engineered EVs as next-generation drug delivery systems.
Engineering extracellular vesicles for cancer therapy: recent advances and challenges in clinical translation

Sha Li,Jinliang Xu,Jun Qian,Xihui Gao

DOI: https://doi.org/10.1039/d0bm01385d

2020-01-01

Biomaterials Science

Abstract:Extracellular vesicles (EVs) are receiving increasing attention in recent years in the field of cancer treatment. EVs contain specific contents closely related to their donor cells, such as miRNAs, proteins and dsDNAs. As endogenous vesicles, EVs naturally have the characteristics of low toxicity and low immunogenicity and can stably pass through the circulatory system to reach the recipient cells, which make them good carriers to deliver therapeutic agents such as nucleic acid sequences and chemotherapeutics. In many preclinical studies and clinical trials, EVs have demonstrated their unlimited advantages in the field of cancer therapy. However, there are still some challenges that restrict their clinical application, such as yield, heterogeneity, safety, and specificity. In this review, we will focus on the latest breakthrough of EVs in the field of cancer treatment and discuss the challenges in the clinical translation of EVs.
Guidelines for clinical translation and commercialization of extracellular vesicles and exosomes based therapeutics

Ke Cheng,Raghu Kalluri

DOI: https://doi.org/10.1016/j.vesic.2023.100029

2023-12-01

Extracellular Vesicle

Abstract:Extracellular vesicles (EVs) are lipid-bilayer delimited membrane structures released by cells, and play a role in intercell communication and disease development. The Global market for EVs in diagnostic and therapeutic applications is expanding. This review maps the current status of EV industry, summarizes the recent advances in EV manufacturing, and focuses on preclinical research involving EVs. The complexity and heterogeneity of EVs provide new opportunities for the development of clinical-grade EV products. The standardization of manufacturing and robust quality control must meet all the Food and Drug Administration requirements and expectations. We believe the evolution of EV research and their mass production with stringency will open a new era of EV-based products in the near future.
Emerging technologies for engineering of extracellular vesicles

Xin Zhou,Qing Huang,Yang Jiang,Huijing Tang,Luhan Zhang,Danyang Li,Yunsheng Xu

DOI: https://doi.org/10.3389/fbioe.2023.1298746

IF: 5.7

2023-11-09

Frontiers in Bioengineering and Biotechnology

Abstract:Extracellular vesicles (EVs) are lipid-bilayer membrane-enclosed vesicles that are secreted by all cell types. Natural EVs contain biological information such as proteins, nucleic acids, and lipids from their parent cells. Therefore, EVs have been extensively studied as diagnostic biomarkers and therapeutic tools under normal and pathological conditions. However, some drawbacks, including low yield, poor therapeutic effects, lack of imaging, and targeting capacity of natural EVs, still need to be improved. Emerging engineering technologies have rendered EVs new properties or functionalities that broadened their applications in the biomedical field. Herein, in this review, we gave a brief overview of advanced strategies for EV engineering. We focused on pre-treatment of parent cells to regulate their released EVs. Meanwhile, we summarized and discussed the direct modification of EVs to achieve drug loading, imaging, and targeting functionalities for downstream applications.

multidisciplinary sciences
Efficient, High-Quality Engineering of Therapeutic Extracellular Vesicles on an Integrated Nanoplatform

Yuqiong Wang,Kuan Yang,Zhaocun Huang,Yusen Wang,Ao Xiao,Xinran Jiang,Feng Liu,Zixiang Wang,Hong Sun,Yongyan Hu,Yibo Wang,Han Wu,Long Lin,Zhiyuan Jin,Lamei Du,Jiazheng Sun,Jiaqi Liu,Dedong Yin,Shenshen Kong,Kun Song,Xing Chen,Mingzhu Yang,Wei Mu,Zhaojian Liu,Xinge Yu,Lingqian Chang

DOI: https://doi.org/10.1021/acsnano.4c04730

IF: 17.1

2024-10-26

ACS Nano

Abstract:Engineered extracellular vesicles (EVs) have been recognized as important therapeutics for gene and cell therapy. To achieve clinically desired therapy, technologies for EV engineering have high demands on the efficacy in producing EVs and their qualities, which, however, remain challenging to conventional routes due to their limited control on therapeutic payload delivery, EV secretion, and extracellular microenvironments. Here, we report a nanoplatform (denoted as PURE) that enables efficient...

materials science, multidisciplinary,chemistry, physical,nanoscience & nanotechnology
Engineered extracellular vesicles for bone therapy

Yingying Jiang,Jiadong Li,Xu Xue,Zhifeng Yin,Ke Xu,Jiacan Su

DOI: https://doi.org/10.1016/j.nantod.2022.101487

IF: 17.4

2022-06-01

Nano Today

Abstract:Extracellular vesicles, which are secreted by living cells and play a critical role in cellular communication, have emerged as a promising cell-free strategy in the treatment of many diseases. Recently, EVs are considered excellent delivery systems for various therapeutic agents, including nucleic acids, proteins, drugs, and nanomaterials, owing to their superior physiochemical stability and biocompatibility. Yet, drawbacks such as the the uncertain distribution, unfavorable therapeutic efficiency and low yields are still the primary obstacles that hinder the application of EVs in the clinical. An increasing number of studies show that EVs can be "internally" engineered via cargo loading and "externally" engineered via surface modification to track their distributions, obtain scalable production and improve bone-targeting capacity for bone therapy. Herein, we provide a brief overview of the present applications and therapeutic mechanism of EVs for bone-related diseases. Thereafter, a comprehensive overview of methodological advances made recently in internally and externally engineering EVs is presented. Moreover, the potential applications of modified EVs are discussed by presenting prominent examples for the treatment of osteoarthritis, osteoporosis, and bone fracture and defects, as well as the prospective engineering approaches to address these issues.

materials science, multidisciplinary,nanoscience & nanotechnology,chemistry
Clinical Translation of Extracellular Vesicles

Aayushi Ghodasara,Aun Raza,Joy Wolfram,Carlos Salomon,Amirali Popat

DOI: https://doi.org/10.1002/adhm.202301010

IF: 10

2023-07-09

Advanced Healthcare Materials

Abstract:In this perspective, the current trends, emerging trends and challenges associated with the clinical translation of extracellular vesicles (EVs) are discussed, and completed and selected ongoing clinical trials using EVs are highlighted. Extracellular vesicles (EVs) occur in a variety of bodily fluids and have gained recent attraction as natural materials due to their bioactive surfaces, internal cargo, and role in intercellular communication. EVs contain various biomolecules, including surface and cytoplasmic proteins; and nucleic acids that are often representative of the originating cells. EVs can transfer content to other cells, a process that is thought to be important for several biological processes, including immune responses, oncogenesis, and angiogenesis. An increased understanding of the underlying mechanisms of EV biogenesis, composition, and function has led to an exponential increase in preclinical and clinical assessment of EVs for biomedical applications, such as diagnostics and drug delivery. Bacterium‐derived EV vaccines have been in clinical use for decades and a few EV‐based diagnostic assays regulated under Clinical Laboratory Improvement Amendments have been approved for use in single laboratories. Though, EV‐based products are yet to receive widespread clinical approval from national regulatory agencies such as the United States Food and Drug Administration (USFDA) and European Medicine Agency (EMA), many are in late‐stage clinical trials. This perspective sheds light on the unique characteristics of EVs, highlighting current clinical trends, emerging applications, challenges and future perspectives of EVs in clinical use.

nanoscience & nanotechnology,engineering, biomedical,materials science, biomaterials

[Laxatives: marketing, mechanism of action and clinical effects].

Development of Extracellular Vesicle Therapeutics: Challenges, Considerations, and Opportunities

Engineering Extracellular Vesicles as Delivery Systems in Therapeutic Applications

Extracellular Vesicles As Nanomedicine: Hopes And Hurdles In Clinical Translation

Biological Functions and Biomedical Applications of Extracellular Vesicles Derived from Blood Cells

Engineered Extracellular Vesicles: Tailored-Made Nanomaterials for Medical Applications

Extracellular vesicles: Emerging tools as therapeutic agent carriers

Engineered Extracellular Vesicles: A Potential Treatment for Regeneration

Advances of engineered extracellular vesicles-based therapeutics strategy

Therapeutic Applications of Extracellular Vesicles: Clinical Promise and Open Questions

Different Sourced Extracellular Vesicles and Their Potential Applications in Clinical Treatments

Extracellular Vesicles in Therapeutics: A Comprehensive Review on Applications, Challenges, and Clinical Progress

Engineered Extracellular Vesicles as a Targeted Delivery Platform for Precision Therapy

From Promise to Reality: Bioengineering Strategies to Enhance the Therapeutic Potential of Extracellular Vesicles

Engineering extracellular vesicles for cancer therapy: recent advances and challenges in clinical translation

Guidelines for clinical translation and commercialization of extracellular vesicles and exosomes based therapeutics

Emerging technologies for engineering of extracellular vesicles

Efficient, High-Quality Engineering of Therapeutic Extracellular Vesicles on an Integrated Nanoplatform

Engineered extracellular vesicles for bone therapy

Clinical Translation of Extracellular Vesicles